The Valley Desk

NCT01702428 · Interventional trial

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Overall registry status Completed

Phase 3

Conditions Measles, Mumps, Rubella

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov